/PRNewswire/ Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Biogen Inc. (Nasdaq: BIIB) announced the decision to terminate development of BIIB105 (ION541).
Biogen Inc : Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Development of BIIB105, an investigational antisense oligonucleotide for amyotrophic lateral sclerosis (ALS), will be discontinued based on data from the.
Cumulus Neuroscience Presents Key Data at the 2023 ENCALS Annual Meeting on Patients with Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ - Raya Therapeutic Inc., ("Raya") a mission-driven company focused on the treatment of neurodegenerative diseases, has entered into an early-stage.